The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Eli Lilly (LLY) and Company announced at plans to bolster its domestic medicine production across therapeutic areas by building four new ...

Eli Lilly announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will p ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, ...

Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients: Indianapolis Wednesday, February 26, 2025, 17:00 Hrs [IST] Eli Lilly and Company announ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...